Improved Survival with Single-Agent Paclitaxel Consolidation/Maintenance Therapy in Advanced Ovarian Carcinoma John P. Micha, et al. - Conclusion: We recognize the important limitations of this study, particularly its sample size and nonrandomized nature. However, these data provide support for the conclusion that paclitaxel 'maintenance/consolidation' therapy may favorably impact overall and progression-free survival in advanced ovarian cancer patients who achieve an excellent response to primary platinum-based chemotherapy [more...]
